The Attractiveness of Investing In ProQR Therapeutics N.V. (PRQR) is Growing


In the meantime, Cantor Fitzgerald upgraded its ProQR Therapeutics N.V. [PRQR] rating to an Overweight from a a Neutral in a research note published on Tuesday, December 22, 2022; the price target was increased to $5 from $0.80. PT values the company’s stock at a premium of 44.2 to its Tuesday closing price. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in mid February from “a Buy” to “a Neutral”. Stifel also remained covering PRQR and has decreased its forecast on February 11, 2022 with a “Hold” recommendation from previously “Buy” rating. Raymond James revised its rating on February 11, 2022. It rated PRQR as “a Mkt perform” which previously was an “a Strong buy”.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance Review of PRQR

On Tuesday, ProQR Therapeutics N.V. [NASDAQ:PRQR] saw its stock jump 6.08% to $2.79. On the same session, the stock had its day’s lowest price of $2.6036, but rose to a high of $2.90. Over the last five days, the stock has lost -20.74%. ProQR Therapeutics N.V. shares have fallen nearly -24.59% since the year began. Nevertheless, the stocks have fallen -44.97% over the past one year. While a 52-week high of $6.15 was reached on 01/03/23, a 52-week low of $0.53 was recorded on 01/19/23. SMA at 50 days reached $2.12, while 200 days put it at $1.13. A total of 1.68 million shares were traded, compared to the trading of 1.05 million shares in the previous session.

Levels Of Support And Resistance For PRQR Stock

The 24-hour chart illustrates a support level at 2.63, which if violated will result in even more drops to 2.47. On the upside, there is a resistance level at 2.93. A further resistance level may holdings at 3.06. The Relative Strength Index (RSI) on the 14-day chart is 49.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.49, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.54%. Stochastics %K at 24.19% indicates the stock is a holding.

How much short interest is there in ProQR Therapeutics N.V.?

A steep rise in short interest was recorded in ProQR Therapeutics N.V. stocks on Oct 13, 2022, growing by 0.9 million shares to a total of 1.25 million shares. Yahoo Finance data shows the prior-month short interest on Sep 14, 2022 was 0.35 million shares. There was a rise of 72.04%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 1.86% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.35.

ProQR Therapeutics N.V. [PRQR] – Who Are The Largest Shareholders?

In filings from Privium Fund Management BV, it is revealed that the company now owns 5,344,446 shares, or roughly 7.50% of the outstanding PRQR shares. Over the last quarter, Prosight Management LP purchased 8,781 shares of ProQR Therapeutics N.V., while Monaco Asset Management SAM bought 0 shares. At present, FIL Investment Advisors is holding 899,257 shares valued at $3.33 million. DAFNA Capital Management LLC owned 649,383 shares of the company at the time of its most recent 13F filing, worth $2.4 million.

According to FactSet, ProQR Therapeutics N.V.’s share price will average $3.27 in the next year, based on opinions of analysts polled by the firm. This is up nearly 42.59 percent from its previous closing price of $2.63. Analysts expect ProQR Therapeutics N.V. stock to reach the higher price of $5.00, while the lowest price estimate is $0.94. However, 8 analysts have rated PRQR stock as an Overweight in their predictions for 2023. The most recent change occurred on February 01, 2022 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $19 price target.


Please enter your comment!
Please enter your name here